Press Releases

Year

September 18, 2019

Vertical Pharmaceuticals LLC, an Osmotica company, Announces Presentation of Phase III RVL-1201 Clinical Trial Data in Patients with Acquired Blepharoptosis (droopy eyelid)

Results from Three Pivotal Phase III Efficacy and Safety Trials (Studies RVL-1201-201, 202 and 203) to Be Presented at Multiple Global Congresses BRIDGEWATER, N.J. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc (“Osmotica” or the

September 17, 2019

Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Submission of New Drug Application for RVL-1201

--RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) is a potential first-in-class pharmacologic treatment option for acquired blepharoptosis (droopy eyelid)-- BRIDGEWATER, N.J. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica

September 4, 2019

Osmotica Pharmaceuticals plc Announces Results of Extraordinary General Meeting

BRIDGEWATER, N.J. , Sept. 4, 2019 /PRNewswire/ -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced results of the Company's Extraordinary General Meeting. At the Extraordinary General Meeting of the Company

August 28, 2019

Osmotica Pharmaceuticals plc to Present at 2019 Wells Fargo Healthcare Conference

BRIDGEWATER, N.J. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Andrew Einhorn , Chief Financial Officer, will present at the 2019 Wells Fargo Healthcare Conference as

August 8, 2019

Osmotica Pharmaceuticals plc Reports Second Quarter 2019 Results

Second quarter 2019 total revenue of $57.5 million On track to submit NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, by end of Q3 2019 BRIDGEWATER, N.J. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc

August 1, 2019

Osmotica Pharmaceuticals plc to Provide Second Quarter 2019 Business and Financial Update on August 8, 2019

BRIDGEWATER, N.J. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 second quarter financial results on Thursday, August 8, 2019 , after

May 30, 2019

Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference

BRIDGEWATER, N.J. , May 30, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison , Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn

May 14, 2019

Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference

BRIDGEWATER, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison , Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn

May 9, 2019

Osmotica Pharmaceuticals plc Reports First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress

First quarter 2019 total revenue of $57.1 million ; net loss of $6.2 million Positive topline results from second Phase III clinical trials of RVL-1201 for ptosis or droopy eyelid BRIDGEWATER, N.J. , May 09, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”)

May 6, 2019

Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (“RVL”) for Acquired Blepharoptosis (ptosis or droopy eyelid)

- Second Phase III Study 202 Meets Primary Endpoint; Provides Additional Evidence of Efficacy and Safety - - Long-term Phase III Study 203 Provides Additional Evidence of Safety - - Company to Host Conference Call on Tuesday, May 7 th at 12pm ET with Dr. Chuck Slonim and Dr.

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investor Relations

News

Press Releases

Press Releases

Press Releases